Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence-based approaches to treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.16561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review.
J Pathol Transl Med
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine (UCI), Irvine, CA, USA.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a clinically indolent lymphoproliferative disorder characterized by accumulation of mature B-cell lymphocytes. Given the common CD5 co-expression, mantle cell lymphoma (MCL) is one of the most important entities in the differential diagnosis. MCL and CLL/SLL might exhibit overlapping morphologic and immunohistochemical features, making diagnosis particularly difficult in cases of composite lymphomas.
View Article and Find Full Text PDFDisease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.
Future Oncol
September 2025
Eli Lilly and Company, Indianapolis, IN, USA.
Aim: The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.
Methods: We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
Future Oncol
September 2025
HEOR & RWE, Global Medical Affairs, BeOne Medicines Ltd, San Carlos, CA, USA.
Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.
Materials & Methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.
Ancestral Origin and Functional Expression of a Hyaluronic Acid Pathway Complement in Mussels.
Biology (Basel)
July 2025
Institute of Science and Technology Austria (ISTA), 3400 Klosterneuburg, Austria.
Hyaluronic acid (HA) is a key extracellular matrix component of vertebrates, where it mediates cell adhesion, immune regulation, and tissue remodeling through its interaction with specific receptors. Although HA has been detected in a few invertebrate species, the lack of fundamental components of the molecular HA pathway poses relevant objections about its functional role in these species. Mining genomic and transcriptomic data, we considered the conservation of the gene locus encoding for the (XLINK) in marine mussels as well as its expression patterns.
View Article and Find Full Text PDFRecent advances and future directions in newly diagnosed mantle cell lymphoma.
Expert Opin Pharmacother
September 2025
Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Introduction: There have been recent major advances in the management and treatment of mantle cell lymphoma (MCL). This uncommon subtype of mature B-cell lymphoma has a heterogeneous clinical course, including a spectrum of indolent and aggressive disease. While historically regarded as an incurable disease with a poor long-term prognosis, recent developments have improved outcomes.
View Article and Find Full Text PDF